Core Viewpoint - Silver Dollar Resources Inc. has announced a private placement offering aiming to raise between $950,000 and $4,000,000 through the sale of units priced at $0.35 each, with the proceeds intended for exploration activities and working capital [1][3]. Group 1: Offering Details - The offering will consist of units, each comprising one common share and one warrant, with warrants allowing the purchase of additional shares at $0.45 within 36 months [2]. - The offering is scheduled to close around the week of September 30, 2025, contingent upon raising the minimum gross proceeds and obtaining necessary approvals [6]. - The agent has the option to sell an additional 1,714,286 units for up to $600,000 in gross proceeds [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to exploration activities at the La Joya Silver Project in Durango, Mexico, and the Ranger-Page Ag-Pb-Zn Project in Idaho [3]. Group 3: Regulatory Compliance - The units will be offered to purchasers in all Canadian provinces except Québec and in offshore jurisdictions, adhering to National Instrument 45-106 regulations [5]. - Securities sold under the offering will not be registered under the U.S. Securities Act and cannot be offered in the U.S. without registration or an exemption [9]. Group 4: Financial Arrangements - The company will pay the agent a cash commission of 6% of the gross proceeds and issue broker warrants equivalent to 6% of the units sold [8].

Ahead of the Senate Banking Committee's confirmation vote on Steven Myron to be Federal Reserve Governor, you told your colleagues that if you're in favor of Federal Reserve independence, then you should vote no. >> Myron was confirmed by the full Senate last night. Today, he is participating in the Fed's monetary policy meeting, but he has not resigned from his position at the White House.He's on a leave of absence. >> How could Myron threaten Federal Reserve independence. So look, Myron is just there to b ...

An uncrewed Northrop Grumman-built spacecraft in orbit experienced an issue with its main engine on Tuesday while attempting to reach the International Space Station to deliver scientific supplies, NA... ...

BlackRock is doubling down on the rapidly expanding active ETF universe with the launch of two mutual fund stalwarts as ETFs. The company launched the iShares Dynamic Equity Active ETF BDYN and the iShares Disciplined Volatility Equity Active ETF BDVL on Tuesday, rounding out its large iShares stable.BDYN has a 0.42% (0.40% net) gross expense ratio and BDVL charges 0.41% (0.40% net).BDYN is approaching key resistance levels. Check the full analysis here.The introductions complement the company’s $50 billion ...

Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. for allegedly misleading investors about the success of its cancer drug RP1, leading to a 77% stock price drop after the FDA rejected its application [1][2]. Group 1: Lawsuit Details - The lawsuit, Jboor v. Replimune Group, Inc., represents investors who purchased Replimune securities between November 22, 2024, and July 21, 2025 [2]. - The FDA issued a "Complete Response Letter" on July 22, 2025, rejecting the Biologics License Application for RP1, which caused a significant sell-off and a 77% decline in stock price [2][3]. - The complaint alleges that Replimune provided a misleadingly optimistic view of RP1's prospects, with the FDA's CRL indicating that the IGNYTE trial was not adequately designed or controlled [3][4]. Group 2: Regulatory Concerns - The lawsuit claims that Replimune failed to disclose regulatory concerns that directly contributed to the stock's collapse, resulting in substantial losses for investors [4]. - The FDA's rejection letter highlighted fundamental flaws in the IGNYTE trial, including issues with patient heterogeneity and trial design, which compromised the integrity of the data [6][7]. - The company allegedly overstated the likelihood of success for the IGNYTE trial, which the FDA deemed inadequate for approval [7]. Group 3: Investigation and Whistleblower Information - Hagens Berman is actively investigating whether Replimune misled its investors regarding the trial's design and results [5][6]. - Whistleblowers with non-public information about Replimune are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [8].

Core Insights - A rivalry is intensifying between Palantir and Salesforce as Salesforce has launched a new national security business division named Missionforce [1] Company Developments - Salesforce is expanding its business operations into the national security sector with the introduction of Missionforce [1] - This move indicates Salesforce's strategic intent to compete directly with Palantir, which has established a strong presence in the national security domain [1] Industry Implications - The launch of Missionforce by Salesforce could disrupt the current dynamics in the national security technology market, potentially increasing competition for contracts and partnerships [1] - The rivalry may lead to innovation and enhanced service offerings as both companies strive to capture market share in this critical sector [1]

If you want full access to all our reports, data and investing ideas, join The Aerospace Forum , the #1 aerospace, defense and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.In April, I downgraded Howmet Aerospace Inc. PFD Ser A (NYSE: HWM.PR ) to a hold. The preferred stock price has declined 4.6% since then, with a total return of -2.1%. As chances of interest cuts are increasing, I revisit theDhierin runs the invest ...

Core Insights - The article discusses the recent downgrade of Howmet Aerospace Inc. PFD Ser A (NYSE: HWM.PR) to a hold rating, noting a 4.6% decline in the preferred stock price since the downgrade, resulting in a total return of -2.1% [1] Company Analysis - Howmet Aerospace operates in the aerospace, defense, and airline sectors, which are characterized by significant growth prospects [1] - The analysis emphasizes the potential impact of increasing chances of interest rate cuts on the company's performance and investment outlook [1] Investment Strategy - The investing group, The Aerospace Forum, aims to identify investment opportunities within the aerospace, defense, and airline industries, leveraging data-informed analysis [1] - The group provides access to data analytics monitors to support investment decisions [1]

Key TakeawaysUS retail sales demonstrated unexpected strength in July, rising by 0.5%, with August projected to increase by 0.2%, defying a softening labor market and signaling continued consumer resilience despite economic headwinds.Major technology companies, including Microsoft (MSFT), OpenAI (OPENAI), and Oracle (ORCL), are committing hundreds of billions of dollars to expand AI infrastructure globally, with OpenAI alone signing a staggering $300 billion data center pact with Oracle.The labor market sho ...

Core Insights - Eli Lilly's experimental GLP-1 pill demonstrated an approximate 12% reduction in body weight among participants in a 72-week trial, with weight loss stabilizing for most patients [1] Group 1 - The study results were presented at a recent conference, highlighting the effectiveness of the GLP-1 pill in weight management [1] - The trial duration of 72 weeks indicates a long-term assessment of the drug's impact on weight loss [1] - The plateauing of weight loss suggests that while initial results are promising, further investigation may be needed to understand long-term efficacy [1]